ClinicalTrials.gg
CompletedNCT03593200Updated Dec 22, 2020Results posted

A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

A Phase 2 interventional study of Pegcetacoplan in PNH, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-22.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase IIa, open-label, multiple dose, study in patients with PNH who have not received eculizumab (Soliris ®) in the past. A single cohort of subjects is planned for evaluation.

02

Conditions studied

  • PNH

Keywords

  • PNH
  • Paroxysmal Nocturnal Hemoglobinuria
  • Complement inhibitor
  • Anemia
  • Hemoglobinuria
  • Hemolysis
  • Hematologic diseases
  • Extravascular hemolysis (EVH)
  • Intravascular hemolysis (IVH)
  • C3 inhibitor
03

In context

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

This study's enrollment of 4 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.

Browse Hemoglobinuria, Paroxysmal studies →

Lead sponsor

Apellis Pharmaceuticals, Inc. is the lead sponsor of 28 studies on the registry; 3 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Apellis Pharmaceuticals, Inc. became part of Biogen.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old (inclusive)
  • Diagnosed with PNH (white blood cell (WBC) clone >10%)
  • Lactose dehydrogenase (LD) ≥2 times the
  • Screening Ferritin ≥ normal and Total Iron Binding Capacity (TIBC) \< LLN based on central lab reference ranges. If a subject is receiving iron supplements at screening, the investigator must ensure that his/her dose has been stable for 8 weeks prior to enrolment and must be maintained throughout the study
  • Last transfusion within 12 months prior to screening
  • count of >30,000/mm3 at the screening visit
  • >500/ mm3 at the screening visit
  • Women of (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of for the duration of the study
  • Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study
  • Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with pegcetacoplan. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits
  • Willing and able to give

Exclusion criteria

Exclusion Criteria:

  • Prior eculizumab (Soliris®) treatment
  • Active bacterial infection
  • Hereditary complement deficiency
  • History of bone marrow transplantation
  • Concurrent severe aplastic anemia (SAA), defined as currently receiving therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin
  • Participation in any other drug trial or exposure to another investigational agent, device or procedure within 30 days
  • Evidence of prolongation defined as >450 ms for males and >470 ms for females at screening
  • Breast-feeding women
  • History of meningococcal disease
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Experimental: Cohort 1

    270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364\*

    Drug: Pegcetacoplan

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity

    TEAEs were defined as adverse events (AE) that occurred after dosing on Day 1 and up to 30 days after the last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possible, probable, or definite. TEAEs were graded according to the Common Terminology Criteria for Adverse Events (v4.03) based on: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death related to AE.

    Time frame: From Day 1 to 30 days after the last dose (approximately 56 weeks)

  2. Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level

    Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

    Time frame: Baseline and Day 365

  3. Mean Change From Baseline in Haptoglobin Level

    Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

    Time frame: Baseline and Day 365

  4. Mean Change From Baseline in Hemoglobin (Hb) Level

    Hematology assessments of Hb were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

    Time frame: Baseline and Day 365

Secondary outcomes

  1. Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score

    The FACIT-Fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher quality of life (QoL).

    Time frame: Baseline and Day 365

  2. Mean Change From Baseline in Absolute Reticulocyte Count (ARC) Level

    Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

    Time frame: Baseline and Day 365

  3. Mean Change From Baseline in Total Bilirubin Level

    Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

    Time frame: Baseline and Day 365

  4. Mean Number of Red Blood Cell (RBC) Transfusions Per Month

    The number of on-study RBC transfusions was monitored throughout the treatment period.

    Time frame: From Day 1 to Day 364

  5. Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score for QoL

    The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.

    Time frame: Baseline and Day 365

  6. Mean Serum Concentrations of Pegcetacoplan

    Serum concentrations of pegcetacoplan at Day 365 are presented.

    Time frame: Day 365

  7. Mean Area Under the Serum Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration at the End of the Study (AUCtotal)

    The AUCtotal of pegcetacoplan was estimated using a non-compartmental approach.

    Time frame: Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.

  8. Mean Maximum Observed Predose Serum Concentration During the Study (Ctrough,Max,Total)

    The Ctrough,max,total of pegcetacoplan was estimated using a non-compartmental approach.

    Time frame: Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.

07

Results

Posted Dec 22, 2020
Limitations and caveats
Given the small sample size, no conclusions should be drawn from the results summarized and reported as descriptive statistics in Outcome Measures 9-12.

Participant flow

This Phase 2a, open-label, multiple-dose study was conducted in subjects with paroxysmal nocturnal hemoglobinuria (PNH) who had not received treatment with eculizumab (Soliris®) in the past, between 16 August 2018 and 22 October 2019.

Participant flow — Overall Study
MilestonePegcetacoplan 270 mg/Day
Started4
Completed4
Not completed0

Outcome measures

PrimaryNumber of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity

TEAEs were defined as adverse events (AE) that occurred after dosing on Day 1 and up to 30 days after the last dose of study drug. A treatment-related TEAE was defined as a TEAE with a relationship to study drug of possible, probable, or definite. TEAEs were graded according to the Common Terminology Criteria for Adverse Events (v4.03) based on: Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening, Grade 5: Death related to AE.

Time frame:
From Day 1 to 30 days after the last dose (approximately 56 weeks)
Reported as:
Count of participants · Participants
Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity
ParticipantsPegcetacoplan 270 mg/Day
All TEAEs3
Treatment-related TEAEs2
Serious TEAEs1
TEAEs leading to study drug discontinuation0
TEAEs with mild intensity2
TEAEs with moderate intensity0
TEAEs with severe intensity1
TEAEs with life threatening intensity0
TEAEs leading to death0
PrimaryMean Change From Baseline in Lactate Dehydrogenase (LDH) Level

Serum chemistry assessments of LDH were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

Time frame:
Baseline and Day 365
Reported as:
Mean · units/liter
Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level
units/literPegcetacoplan 270 mg/Day
Mean Change From Baseline in Lactate Dehydrogenase (LDH) Level-2322.8 ± 635.41
PrimaryMean Change From Baseline in Haptoglobin Level

Serum chemistry assessments of haptoglobin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

Time frame:
Baseline and Day 365
Reported as:
Mean · grams/liter
Mean Change From Baseline in Haptoglobin Level
grams/literPegcetacoplan 270 mg/Day
Mean Change From Baseline in Haptoglobin Level0.08 ± 0.150
PrimaryMean Change From Baseline in Hemoglobin (Hb) Level

Hematology assessments of Hb were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

Time frame:
Baseline and Day 365
Reported as:
Mean · grams/deciliter
Mean Change From Baseline in Hemoglobin (Hb) Level
grams/deciliterPegcetacoplan 270 mg/Day
Mean Change From Baseline in Hemoglobin (Hb) Level5.27 ± 1.875
SecondaryMean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score

The FACIT-Fatigue scale is a 13 item Likert scaled instrument where the subject was presented with 13 statements and asked to indicate their response as it applied to the past 7 days. The 5 possible responses were 'Not at all' (0), 'A little bit (1), 'Somewhat' (2), 'Quite a bit' (3) and 'Very much' (4). With 13 statements the total score had a range of 0 to 52. Higher score corresponds to a higher quality of life (QoL).

Time frame:
Baseline and Day 365
Reported as:
Mean · score on a scale
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score
score on a scalePegcetacoplan 270 mg/Day
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score6.5 ± 5.45
SecondaryMean Change From Baseline in Absolute Reticulocyte Count (ARC) Level

Hematology assessments of ARC were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

Time frame:
Baseline and Day 365
Reported as:
Mean · ARC/nanoliter
Mean Change From Baseline in Absolute Reticulocyte Count (ARC) Level
ARC/nanoliterPegcetacoplan 270 mg/Day
Mean Change From Baseline in Absolute Reticulocyte Count (ARC) Level-144.3 ± 98.51
SecondaryMean Change From Baseline in Total Bilirubin Level

Serum chemistry assessments of total bilirubin were made at the last measurement prior to the first dose of pegcetacoplan (baseline) and periodically throughout the treatment period.

Time frame:
Baseline and Day 365
Reported as:
Mean · micromoles/liter
Mean Change From Baseline in Total Bilirubin Level
micromoles/literPegcetacoplan 270 mg/Day
Mean Change From Baseline in Total Bilirubin Level-21.53 ± 8.358
SecondaryMean Number of Red Blood Cell (RBC) Transfusions Per Month

The number of on-study RBC transfusions was monitored throughout the treatment period.

Time frame:
From Day 1 to Day 364
Reported as:
Mean · transfusions
Mean Number of Red Blood Cell (RBC) Transfusions Per Month
transfusionsPegcetacoplan 270 mg/Day
Mean Number of Red Blood Cell (RBC) Transfusions Per Month0 (0 to 0)
SecondaryMean Change From Baseline in Linear Analog Scale Assessment (LASA) Score for QoL

The LASA consists of 3 items, where the respondents were asked to rate their perceived level of functioning. Specific domains included activity level, ability to carry out daily activities, and an item for overall QoL. Their level of functioning was reported on a 0 to 100 scale with 0 indicates "As low as could be" and 100 indicates "As high as could be". The combined score ranged from 0 to 300, with higher scores corresponding to a higher QoL.

Time frame:
Baseline and Day 365
Reported as:
Mean · score on a scale
Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score for QoL
score on a scalePegcetacoplan 270 mg/Day
Mean Change From Baseline in Linear Analog Scale Assessment (LASA) Score for QoL66.5 ± 55.75
SecondaryMean Serum Concentrations of Pegcetacoplan

Serum concentrations of pegcetacoplan at Day 365 are presented.

Time frame:
Day 365
Reported as:
Mean · microgram per milliliter (ug/mL)
Mean Serum Concentrations of Pegcetacoplan
microgram per milliliter (ug/mL)Pegcetacoplan 270 mg/Day
Mean Serum Concentrations of Pegcetacoplan622.0 ± 92.13
SecondaryMean Area Under the Serum Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration at the End of the Study (AUCtotal)

The AUCtotal of pegcetacoplan was estimated using a non-compartmental approach.

Time frame:
Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.
Reported as:
Mean · hour*ug/mL
Mean Area Under the Serum Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration at the End of the Study (AUCtotal)
hour*ug/mLPegcetacoplan 270 mg/Day
Mean Area Under the Serum Concentration Versus Time Curve From Time 0 to the Last Measurable Concentration at the End of the Study (AUCtotal)5818803.2534 ± 975444.77662
SecondaryMean Maximum Observed Predose Serum Concentration During the Study (Ctrough,Max,Total)

The Ctrough,max,total of pegcetacoplan was estimated using a non-compartmental approach.

Time frame:
Blood samples were collected predose and at least 2.5 hours post dose on Day 1 and predose on Days 2 up to Day 365.
Reported as:
Mean · ug/mL
Mean Maximum Observed Predose Serum Concentration During the Study (Ctrough,Max,Total)
ug/mLPegcetacoplan 270 mg/Day
Mean Maximum Observed Predose Serum Concentration During the Study (Ctrough,Max,Total)783.5 ± 116.25

Adverse events

Collected over TEAEs were collected from Day 1 up to 30 days after the last dose of study drug (a total of approximately 56 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegcetacoplan 270 mg/Day0/4 (0%)1/4 (25%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventPegcetacoplan 270 mg/Day
Rib fractureInjury, poisoning and procedural complications1/4
Most frequent other events
Most frequent other events
EventPegcetacoplan 270 mg/Day
DizzinessNervous system disorders2/4
ErythemaSkin and subcutaneous tissue disorders2/4
Administration site swellingGeneral disorders1/4
Injection site discolourationGeneral disorders1/4
Injection site erythemaGeneral disorders1/4
Injection site pruritusGeneral disorders1/4
Injection site swellingGeneral disorders1/4
RhinitisInfections and infestations1/4
Scrotal irritationReproductive system and breast disorders1/4
CoughRespiratory, thoracic and mediastinal disorders1/4

Baseline characteristics

The safety set consisted of all subjects who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Pegcetacoplan 270 mg/Day
Mean30.8 ± 11.81
Sex: Female, Male
Sex: Female, Male(Participants)Pegcetacoplan 270 mg/Day
Female3
Male1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Pegcetacoplan 270 mg/Day
White4
Not Hispanic or Latino4
Region of Enrollment
Region of Enrollment(participants)Pegcetacoplan 270 mg/Day
Bulgaria2
Serbia2
08

Study locations

3 sites
  • Acibadem City Clinic MHAT Tokuda EAD Sofia
    Sofia, Bulgaria
  • Specialized Hospital for Active Treatment of Hematologic Diseases EAD, Sofia
    Sofia, Bulgaria
  • Klinički centar Srbije
    Belgrade, Serbia
09

References and documents

Publications

  • Wong RSM, Pullon HWH, Amine I, Bogdanovic A, Deschatelets P, Francois CG, Ignatova K, Issaragrisil S, Niparuck P, Numbenjapon T, Roman E, Sathar J, Xu R, Al-Adhami M, Tan L, Tse E, Grossi FV. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2022 Sep;101(9):1971-1986. doi: 10.1007/s00277-022-04903-x. Epub 2022 Jul 22. PubMed 35869170 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Oct 2019, 14 months.

Results were first posted in Dec 2020, 1 year 2 months after primary completion.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 14 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2018
First posted
Jul 20, 2018
StartActual
Aug 16, 2018
Primary completionActual
Oct 22, 2019
CompletionActual
Oct 22, 2019
Results first posted
Dec 22, 2020
Last update
Dec 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03593200
Responsible party
Sponsor
First posted
Jul 20, 2018
Start date
Aug 16, 2018
Primary completion
Oct 22, 2019
Completion
Oct 22, 2019
Results posted
Dec 22, 2020
Last update
Dec 22, 2020

Study contacts

Federico Grossi, MD, PhD
study director · Study Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion